ImmuneXcite Overview
- Year Founded
-
2007
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
ImmuneXcite General Information
Description
Developer of next generation immune-activating anti-tumor biotherapeutics designed to leverage both the innate and adaptive immune responses to selectively treat a wide range of tumor type. The company's immune-activating anti-tumor biotherapeutics use novel immunotherapy platform that is focused on developing monoclonal antibodies which identifies a fungal carbohydrate responsible for stimulating the innate immune system, enabling health care providers to limit tumor growth and metastasis in patient's body.
Contact Information
Website
www.immunexcite.comCorporate Office
- 266 2nd Avenue
- Suite C
- Waltham, MA 02451
- United States
Corporate Office
- 266 2nd Avenue
- Suite C
- Waltham, MA 02451
- United States
ImmuneXcite Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Out of Business | 12-Oct-2017 | Completed | Out of Business | |||
| 6. Early Stage VC | 01-Feb-2017 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series A1) | 30-Mar-2016 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 20-Dec-2013 | Completed | Generating Revenue | |||
| 3. Grant | 04-Sep-2013 | Completed | Generating Revenue | |||
| 2. Debt - General | 19-Dec-2012 | $984K | $3.4M | Completed | Startup | |
| 1. Seed Round | 03-Jan-2012 | $2.42M | $2.42M | Completed | Startup |
ImmuneXcite Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 |
ImmuneXcite Comparisons
Industry
Financing
Details
ImmuneXcite Competitors (92)
One of ImmuneXcite’s 92 competitors is Araris, a Formerly VC-backed company based in Zurich, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Araris | Formerly VC-backed | Zurich, Switzerland | ||||
| Biocon Biologics | Formerly PE-Backed | Bengaluru, India | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
| Alaunos Therapeutics | Formerly VC-backed | Fort Lauderdale, FL |
ImmuneXcite Patents
ImmuneXcite Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3582810-A1 | ß-1,6-glucan therapeutic antibody conjugates | Pending | 07-Dec-2016 | ||
| EP-3582810-A4 | ß-1,6-glucan therapeutic antibody conjugates | Pending | 07-Dec-2016 | ||
| US-11865135-B2 | ß-1,6-glucan therapeutic antibody conjugates | Active | 07-Dec-2016 | ||
| US-20200030360-A1 | ß-1,6-glucan therapeutic antibody conjugates | Active | 07-Dec-2016 | ||
| EP-3551685-A1 | ß-1,6-glucan trastuzumab antibody conjugates | Inactive | 07-Dec-2016 | A61P35/00 |
ImmuneXcite FAQs
-
When was ImmuneXcite founded?
ImmuneXcite was founded in 2007.
-
Where is ImmuneXcite headquartered?
ImmuneXcite is headquartered in Waltham, MA.
-
What industry is ImmuneXcite in?
ImmuneXcite’s primary industry is Biotechnology.
-
Is ImmuneXcite a private or public company?
ImmuneXcite is a Private company.
-
What is ImmuneXcite’s current revenue?
The current revenue for ImmuneXcite is .
-
How much funding has ImmuneXcite raised over time?
ImmuneXcite has raised $19.3M.
-
Who are ImmuneXcite’s competitors?
Araris, Biocon Biologics, Ability Pharma, Apellis Pharmaceuticals, and Alaunos Therapeutics are some of the 92 competitors of ImmuneXcite.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process